EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Bispecific Antibodies in Solid Tumors: Advances and Challenges

Khine Swe Shan iD, Saba Musleh Ud Din, Shivani Dalal iD, Teresita Gonzalez, Misha Dalal, Pablo Ferraro, Atif Hussein, Michel Vulfovich

International Journal of Molecular Sciences · 18.06.2025 · 26 (12) · 5838

DOI: 10.3390/ijms26125838 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.06.2025. Verfasst von Khine Swe Shan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33028, USA. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Neoplasms, Immunotherapy, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 193 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bispecific antibodies (BsAbs) have shown potential in cancer treatment and have become a rapidly growing field in cancer immunotherapy. Unlike monoclonal antibodies with two identical binding sites, BsAbs simultaneously bind two distinct epitopes on the same or different antigens, allowing for a range of mechanisms of action, including engaging immune cells to kill cancer cells and blocking signaling pathways. Despite regulatory approvals for hematological malignancies in the last decade, their clinical success in solid malignancies has been lacking until recently. There are currently five BsAbs approved by the FDA in the United States for solid tumors—amivantamab, tarlatamab, tebentafusp, zanidatamab and zenocutuzumab—and two BsAbs approved in China—cadonilimab and ivonescimab. Currently, several BsAbs are under clinical development for solid tumors, but are mostly in early phase I and II trials. This review provides an overview of the basic mechanism of action of BsAbs, current FDA-approved BsAbs, and current BsAbs under clinical development, their challenges in clinical use, the management of toxicities, and future directions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificNeoplasmsImmunotherapyAntineoplastic Agents, ImmunologicalHumansAnimals

Stichwörter der Autor:innen

bispecific T cell engagerbispecific antibodiescytokine release syndromepersonalized cancer therapyprecision medicinetargeted therapy

Substanzen

Antibodies, BispecificAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33028, USA.
  • Memorial Health Care, Division of Internal Medicine, Pembroke Pines, FL 33028, USA.
  • Department of Pathology, University of Illinois at Chicago, Chicago, IL 60612, USA.

ORCID-Profile: Khine Swe Shan, Shivani Dalal

Zitieren

APA

Shan, K. S., Musleh Ud Din, S., Dalal, S., Gonzalez, T., Dalal, M., Ferraro, P., Hussein, A., & Vulfovich, M. (2025). Bispecific Antibodies in Solid Tumors: Advances and Challenges. International Journal of Molecular Sciences, 26(12), 5838. https://doi.org/10.3390/ijms26125838

Vancouver

Shan KS, Musleh Ud Din S, Dalal S, Gonzalez T, Dalal M, Ferraro P, et al. Bispecific Antibodies in Solid Tumors: Advances and Challenges. International Journal of Molecular Sciences. 2025;26(12):5838. doi:10.3390/ijms26125838

BibTeX
@article{Shan2025,
  author = {Shan, Khine Swe and Musleh Ud Din, Saba and Dalal, Shivani and Gonzalez, Teresita and Dalal, Misha and Ferraro, Pablo and Hussein, Atif and Vulfovich, Michel},
  title = {Bispecific Antibodies in Solid Tumors: Advances and Challenges},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {12},
  pages = {5838},
  doi = {10.3390/ijms26125838}
}
Kostenlos starten →